Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Lymphoma 3Leukemia 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
RFT5-SMPT-dgA immunotoxin × Lymphoid × Clear all
NCT01378871 2023-06-09

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Albert Einstein College of Medicine

Phase 2 Terminated
1 enrolled 8 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00667017 2018-12-14

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
1 enrolled 1 chart
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00025662 2016-10-28

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
23 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡